Startups
Edit
Heptares Therapeutics
http://www.heptares.com/Last activity: 04.09.2024
Active - Reference to Nxera Pharma
Overview
Location
United Kingdom, England, South Hams
Employees
51-200
Total raised
$21M
Founded date
2007
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 2, 2024 | Nxera Pharma to receive US$35 Million from Neurocrine Biosciences upon positive phase 2 data for partnered Schizophrenia candidate NBI-1117568 | Tokyo, Japan and Cambridge, UK - Nxera Pharma Co., Ltd. - formerly known as Sosei Group or Sosei Heptares – announces it will receive a US$35 million payment from Neurocrine Biosciences, triggered by the successful completion of the Phase 2... |
| Dec 1, 2016 | Heptares acquires G7 Therapeutics for CHF12 million | |
| Feb 23, 2015 | Sosei Acquires Heptares Therapeutics for up to $400M | Sosei Group Corporation (TOKYO:4565), a Japanese biopharmaceutical company with operations in Japan and the UK, acquired Heptares Therapeutics Limited, a UK-based clinical-stage biotechnology company focused on creating novel medicines targ... |
| Jun 27, 2013 | Heptares Therapeutics Raises $21M in Series B Financing | Heptares Therapeutics, a Welwyn Garden City-based drug discovery and development company, raised over $21m in a Series B financing. The round was co-led by the Stanley Family Foundation and existing investor Clarus Ventures, with participat... |
| Jun 27, 2013 | Heptares Therapeutics Secures $21M | WELWYN GARDEN CITY, ENGLAND, Leading GPCR drug discovery and development company, today announced it has raised over US$21 million in a Series B financing. >> Click here for more funding data on Heptares Therapeutics >> To e... |
| Jun 1, 2011 | Taylor Vinters advise Heptares Therapeutics on collaboration with global giant AstraZeneca | Taylor Vinters advise Heptares Therapeutics on collaboration with global giant AstraZeneca 01-06-2011 Taylor Vinters’ Commercial and Technology lawyers have been advising clients, Heptares Therapeutics, a UK Medical Research Council spin-ou... |
Reviews 0
FAQ about Heptares Therapeutics
When was Heptares Therapeutics founded?
Heptares Therapeutics was founded in 2007.
How much funding has Heptares Therapeutics raised?
Heptares Therapeutics has raised $21M in total across 1 funding round.
What has the press written about Heptares Therapeutics?
Parsers VC has collected 7 articles mentioning Heptares Therapeutics, among them “Nxera Pharma to receive US$35 Million from Neurocrine Biosciences upon positive phase 2 data for partnered Schizophrenia candidate NBI-1117568” (Sep 2, 2024) and “Heptares acquires G7 Therapeutics for CHF12 million” (Dec 1, 2016).
Is Heptares Therapeutics still active?
Yes, Heptares Therapeutics is active; its latest activity on Parsers VC dates from Sep 4, 2024.